Drug intelligence / Profile preview

DW1350

Development stage: Discontinued
Lead developer: Dongwha Pharmaceutical
Modality: Small Molecules

Overview

DW1350 is a small molecule leukotriene B4 (LTB4) receptor antagonist originally developed by Dong Wha Pharm. It specifically targets the LTB4 receptor (LTB4R) to block the pro-inflammatory effects of LTB4, which is a potent chemoattractant for leukocytes. While initially investigated for potential applications in endocrinology and metabolic disorders, its clinical development has been discontinued globally. It is currently utilized primarily as a research tool in laboratory settings.

Targets

LTB4R (Leukotriene B4 Receptor 1)

Beyond the preview

Go deeper on DW1350.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW1350.

Explore the full profile